Metformin in prostate cancer
Mené sur 1 874 patients atteints d'un cancer de la prostate hormonosensible et de stade métastatique (âge médian : 69 ans), cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, de l'ajout de metformine à un traitement anti-androgénique
The treatment of metastatic hormone-sensitive prostate cancer has changed substantially over the past decade, with androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPI) with or without docetaxel becoming the standard of care.1 The median overall survival for metastatic hormone-sensitive prostate cancer now exceeds 60 months, with patients living with castration levels of testosterone for many years. Therefore, adjunctive and minimally toxic strategies to mitigate the adverse metabolic effects of low androgen concentrations and improve clinical outcomes and quality of life are huge unmet needs. In this context, metformin, a commonly prescribed and widely used medication, has gained considerable interest for its favourable metabolic effects and anti-neoplastic effect through activating adenosine monophosphate-activated protein kinase, which inhibits the mTOR pathway, suppressing insulin and reducing androgen receptor expression.2
The Lancet Oncology , commentaire, 2025